CHICAGO : Final data from Gilead Sciences Inc's antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said on Thursday.In patients who were on oxygen when they first got the drug, remdesivir - sold under the brand Veklury - reduced recovery time by seven days compared with placebo after 29 days, according to the 1,062-patient study, published in the New England Journal of Medicine.The final study looked at data at 29 days of treatment, versus a preliminary study released in May that reported results after 15 days.Gilead's drug was among the first to be used as a treatment for the novel.